ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)
Registration number: 1985/002935/06
Share code: APN
ISIN: ZAE000066692
LEI: 635400ZYSN1IRD5QWQ94
and its subsidiaries
(collectively “Aspen” or “the Group”)

CONFIRMATION OF RELEASE OF INTEGRATED REPORT AND FURTHER NOTICE OF ANNUAL GENERAL
MEETING TO BE HELD ON 8 DECEMBER 2022

1. POSTING OF AGM NOTICE AND ABBREVIATED REPORT

Shareholders are advised that the Company’s Integrated Report for the year ended 30 June 2022 has been
finalised and that the notice of the annual general meeting (“AGM”) to be held at its Durban offices on
8 December 2022 is in the process of being posted to shareholders, along with a set of abbreviated annual
financial statements (“AFS”). The following documents are now available on the Company’s website
www.aspenpharma.com (at the following link https://www.aspenpharma.com/investor-information/):

 - Integrated Report for the 2022 financial year;
 - Notice of AGM and proxy in respect of the AGM to be held on 8 December 2022;
 - Reports of the Aspen Audit & Risk and Social & Ethics committees for the 2022 financial year;
 - Full AFS for the 2022 financial year (as approved by the Company’s Board on 4 October 2022 and
   uploaded to the Company’s website on that date – shareholders are referred to the No Change
   Statement and Notice of Annual General Meeting as released on 4 October 2022); and
 - Various other reports supplementary to the Integrated Report.

 2. NOTICE OF AGM

 Further notice is hereby given that the 24th annual general meeting of the shareholders of the Company will
 be held at Aspen Place, 9 Rydall Vale Park, Douglas Saunders Drive, La Lucia Ridge Office Park, Durban, Kwa-
 Zulu Natal, on Thursday, 8 December 2022 at 10:00. Should you choose to attend the meeting in person,
 please contact the Company Secretary & Group Governance Officer at rverster@aspenpharma.com / 031
 580 8624 by no later than 10:00 on Tuesday, 6 December 2022 in order for seating arrangements to be
 confirmed.

 The record date on which a person must be registered as a shareholder in the register of the Company for
 purposes of being entitled to attend and participate in, and speak and vote at, the meeting is Friday,
 2 December 2022. Accordingly, the last day to trade in order to be registered in the register of members of
 the Company and therefore be eligible to participate in and vote at the annual general meeting is Tuesday,
 29 November 2022. Shareholders are requested, but are not obliged, to submit their completed forms of
 proxy to the Company’s transfer secretaries (JSE Investor Services) before 10:00 on Tuesday, 6 December
 2022.

 Shareholders who, for whatever reason, experience postal delays and, as a consequence, do not
 receive the notice of the AGM in time to submit proxy forms to the Company’s share transfer
 secretaries (JSE Investor Services) are requested to access the notice of AGM and other documents
 referred to above on the Company’s website www.aspenpharma.com. A printable version of these
 documents in PDF format can also be emailed to shareholders upon request to the Company Secretary
 – rverster@aspenpharma.com or +27 31 580 8624.
 Electronic participation
 Shareholders or their proxies or representatives may participate in (but not vote at) the meeting by way
 of telephone / video conference call, and if they wish to do so:
 • Must contact the Company Secretary & Group Governance Officer (by email at the address
      rverster@aspenpharma.com) by no later than 10:00 on Friday 2 December 2022 in order to obtain
      the dial-in details / meeting link in order to participate in the meeting;
 • Will be required to provide reasonably satisfactory identification; and
 • Will be billed separately by their own service providers for the costs incurred in respect of their
      telephone / video call to participate in the meeting.

3. BROAD-BASED BLACK ECONOMIC EMPOWERMENT CERTIFICATE

Shareholders are hereby notified that in accordance with the JSE Listings Requirements, the Company's
B-BBEE compliance report in terms of section 13G(2) of the Broad-Based Black Economic Empowerment
Act 53 of 2003, read with the Broad-Based Black Economic Empowerment Act 46 of 2013, is in the process
of being submitted to the BEE Commission and will be made available on the Company’s website
www.aspenpharma.com as soon as the submission process has completed. A further announcement in
this regard will be made to shareholders.



Durban
28 October 2022

Sponsor
Investec Bank Limited